| On Heels of $100M Financing, Annexon Bio Aims to Tack On More Via IPO | Sarah de Crescenzo | 07/06/20 | San Francisco |
| Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases | Frank Vinluan | 07/06/20 | Boston |
| The 2020 National Xconomy Awards Expands, Goes Virtual & Reopens Nomination Period | Editors | 07/06/20 | National |
| MEI Pharma, Helsinn Scuttle Cancer Drug Trial After Miss on Efficacy | Sarah de Crescenzo | 07/02/20 | San Diego |
| Moderna: Speed of COVID 19 Vaccine Hinges On Enrolling Right Patients | Sarah Karlin-Smith | 07/02/20 | National |
| Data Quantity, Complexity Drives Use of AI in Drug Discovery and Testing | Frank Vinluan | 07/02/20 | San Francisco |
| Annexon Adds On $100M to Advance Antibodies to Treat Neurodegeneration | Sarah de Crescenzo | 07/01/20 | San Francisco |
| BioNTech’s mRNA COVID-19 Vaccine Shows Early Signs of Sparking Immunity | Frank Vinluan | 07/01/20 | Europe |
| Amylyx Adds $30M to Press On With Neuro Drug for ALS, Alzheimer’s | Frank Vinluan | 07/01/20 | Boston |
| Bolt Bio Adds $93.5M to Move Ahead Immune-Stimulating Cancer Drugs | Sarah de Crescenzo | 07/01/20 | San Francisco |
| Chiesi Licenses Bioasis Tech to Tackle Brain Symptoms of Rare Diseases | Sarah de Crescenzo | 07/01/20 | Boston |
| Ultragenyx Pharma Wins FDA’s First Drug Nod for Rare Metabolic Disorder | Frank Vinluan | 06/30/20 | San Francisco |
| Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later | Frank Vinluan | 06/30/20 | Boston |
| Code for Cures: Life Sciences Thrives on San Francisco’s Software Heritage | Sarah de Crescenzo | 06/30/20 | San Francisco |
| Roche Gets FDA OK for Injectable Version of Breast Cancer Drug | Sarah de Crescenzo | 06/29/20 | San Diego |
| FDA Again Dings Heron’s Opioid Alternative Over “Nonclinical Issues” | Sarah de Crescenzo | 06/29/20 | San Diego |
| FDA Says “No” to Intercept Pharma’s NASH Drug, Asks for More Data | Frank Vinluan | 06/29/20 | New York |
| New Xconomy Special Report: Biopharma and Tech Innovators Summer 2020 | Editors | 06/29/20 | National |
| With Peanut Patch in FDA Purgatory, DBV Plans Layoffs to Stretch Cash | Sarah de Crescenzo | 06/26/20 | National |
| Eye Inflammation Dooms AbbVie Wet AMD Drug to an FDA Rejection | Frank Vinluan | 06/26/20 | National |
| Artiva Bio Raises $78M to Broaden Access to Cancer Cell Therapies | Sarah de Crescenzo | 06/26/20 | San Diego |
| Bio Roundup: Gilead’s Pionyr Grab, Relay to IPO, Unicorn Sana & More | Sarah de Crescenzo | 06/26/20 | National |
| CSL Behring Bolsters Hemophilia Lineup With Deal for uniQure’s Gene Therapy | Frank Vinluan | 06/25/20 | Philadelphia |
| FDA Official: New “Playbook” Needed for CMC Reviews of Gene Therapy Products | Joanne S. Eglovitch | 06/25/20 | National |
| Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs | Sarah de Crescenzo | 06/25/20 | Boston |
| La Jolla Pharma Steps In With Better Offer, Wins Tetraphase Bidding War | Frank Vinluan | 06/24/20 | San Diego |
| AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis | Frank Vinluan | 06/24/20 | National |
| Reneo Readies for Global Test of Drug for Rare Mitochondrial Disease | Sarah de Crescenzo | 06/23/20 | San Diego |
| Gilead Grabs Option to Acquire Pionyr & Its Clinic-Bound Immunotherapies | Sarah de Crescenzo | 06/23/20 | San Francisco |
| Invitae Makes a Precision Oncology Push With $886M Deal for ArcherDx | Frank Vinluan | 06/22/20 | San Francisco |
